| name | target-competition |
| description | Analyze target competitive landscape including existing drugs, pipeline companies,
differentiation opportunities, and market maturity assessment.
Keywords: target competition, landscape, differentiation, pipeline analysis, market share
|
| category | Competitive Intelligence |
| tags | ["competition","landscape","pipeline","differentiation","market"] |
| version | 1.0.0 |
| author | Drug Discovery Team |
| dependencies | ["drugbank","chembl","pharma-projects","citeline"] |
Target Competition Skill
Comprehensive competitive landscape analysis for targets.
Quick Start
/target-compete EGFR --full
/competition "KRAS G12C" --include pipeline,patents,market
/landscape --target "PD-1" --by-phase
Competition Dimensions
1. Approved Drugs
| Metric | Analysis |
|---|
| Number approved | Competitive intensity |
| Classes/mechanisms | Differentiation opportunities |
| First-in-class | Innovation level |
| Generics/biosimilars | Erosion risk |
| Market share leaders | Key competitors |
2. Pipeline Drugs
| Metric | Analysis |
|---|
| Phase 3 | Near-term competition |
| Phase 2 | Mid-term competition |
| Phase 1 | Future competition |
| Novel mechanisms | Innovation potential |
3. Company Coverage
| Metric | Analysis |
|---|
| Big Pharma | Institutional interest |
| Biotech | Innovation sources |
| Emerging markets | Global competition |
4. Patent Landscape
| Metric | Analysis |
|---|
| Active patents | IP barriers |
| Expiration timeline | FTO timeline |
| White space | Opportunity areas |
Output Structure
# Target Competition: KRAS G12C
## Competitive Landscape Summary
| Dimension | Assessment |
|-----------|------------|
| Approved drugs | 2 (Sotorasib, Adagrasib) |
| Pipeline drugs | 15 |
| Active companies | 18 |
| Patent density | Medium |
| Market maturity | Early-growth |
**Overall Competition**: Medium-High
## Approved Drugs
| Drug | Company | Approval Year | Sales (2023) | Market Share |
|------|---------|--------------|---------------|--------------|
| Sotorasib | Amgen | 2021 | $0.8B | 45% |
| Adagrasib | Mirati | 2022 | $0.2B | 15% |
| Others (off-label) | Various | - | $0.5B | 40% |
## Pipeline Analysis
### Phase 3
| Drug | Company | Differentiation | Timeline |
|------|---------|-----------------|----------|
| GDC-6036 | Gilead | CNS-penetrant | 2025 |
| JDQ443 | J&J | Combination | 2026 |
### Phase 2
| Drug | Company | Differentiation |
|------|---------|-----------------|
| RMC-6236 | Revolution | Oral macrocycle |
| BI 1701963 | Boehringer | Pan-KRAS |
### Phase 1
| Drug | Company | Novel Mechanism |
|------|---------|-----------------|
| 4 compounds | Various | Degraders |
| 3 compounds | Various | Allosteric |
## Company Analysis
### Big Pharma Activity
| Company | Pipeline | Strategy |
|----------|----------|----------|
| Amgen | 2 assets | Market leader |
| Mirati | 2 assets | Innovation |
| J&J | 3 assets | Multiple approaches |
| Roche | 2 assets | Combinations |
### Biotech Activity
| Company | Pipeline | Focus |
|----------|----------|-------|
| Revolution Medicine | 2 assets | Oral macrocycle |
| Kura Oncology | 1 asset | Selective inhibitor |
| BridgeBio | 2 assets | Different indications |
## Patent Landscape
| Metric | Value |
|--------|-------|
| Active patents (US) | 45 |
| Key patents expiring | 2033-2037 |
| Freedom to operate | Challenging |
| White space | Allosteric, degraders |
## Differentiation Opportunities
### Unmet Needs
1. **CNS penetration**: Current drugs don't reach brain mets
2. **Resistance mutations**: G12D, Y96D emerging
3. **Combination therapy**: With SHP2, SOS1
4. **Pan-KRAS**: Beyond G12C
### White Space
| Area | Competition | Opportunity |
|------|-------------|------------|
| CNS-penetrant | Low | High |
| G12D inhibitors | Medium | Medium |
| Pan-KRAS | Medium | Medium |
| Degraders | Low | High (early) |
| Allosteric | Low | Medium |
## Market Dynamics
### Market Evolution
2020: No approved drugs
2021: Sotorasib approval (first-in-class)
2022: Adagrasib approval (second-in-class)
2023-2025: Generics, biosimilars enter
2026+: Next-generation launch (CNS, combinations)
### Future Outlook
| Year | Event | Impact |
|------|--------|--------|
| 2025 | GDC-6036 launch | CNS opportunity |
| 2027 | Key patents expire | Generic entry |
| 2028 | Multiple 4th-gen | Market fragmentation |
## Strategic Recommendations
### For New Entrants
**Avoid**: Me-too G12C inhibitors (crowded)
**Consider**:
- CNS-penetrant molecules
- Resistance mutation coverage
- Novel mechanisms (degraders, covalent allosteric)
- Combination approaches
**Differentiation Strategies**:
1. **CNS penetration**: Brain metastasis indication
2. **Pan-KRAS**: Broad mutation coverage
3. **Combination-first**: Co-develop with SHP2/SOS1
4. **Resistance-focused**: Target emerging mutations
Competition Scoring
Market Maturity Index
| Score | Description | Strategy |
|---|
| 1 | Novel target, no competition | First-in-class opportunity |
| 2 | Early competition | Fast follow opportunity |
| 3 | Multiple approved | Differentiation needed |
| 4 | Crowded, generics | Avoid or niche focus |
Competitive Intensity
| Dimension | Weight | Score |
|---|
| Approved drugs | 30% | 3/5 |
| Pipeline diversity | 25% | 4/5 |
| Patent density | 20% | 3/5 |
| Company interest | 15% | 5/5 |
| Innovation rate | 10% | 4/5 |
Overall: 3.8/5 (High competition)
Running Scripts
python scripts/target_competition.py KRAS --full
python scripts/target_competition.py EGFR --pipeline
python scripts/target_competition.py ALK --patents
python scripts/target_competition.py BRAF --companies
Reference
Best Practices
- Include off-label: Approved drugs used in other indications
- Track discontinued: Why did programs fail?
- Assess innovation quality: Not all Phase 1s equal
- Monitor startups: Often most innovative
- Check conference abstracts: Early pipeline visibility
Common Pitfalls
| Pitfall | Solution |
|---|
| Ignoring off-label use | Include real-world usage |
| Over-counting pipeline | Track active programs only |
| Missing discontinued | Check for terminated trials |
| Late-stage blind spot | Monitor conference abstracts |
| Geographic bias | Include China, Japan, EU |
